Travere Therapeutics (TVTX) Operating Leases (2019 - 2026)
Travere Therapeutics' (TVTX) quarterly Operating Leases came in at $9.6 million in Q1 2026, down 54.54% YoY from $21.0 million in Q1 2025, and down 14.08% on a QoQ basis from $11.1 million in Q4 2025.
Travere Therapeutics (TVTX) Operating Leases (2019 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 8 years of Operating Leases data on file, last reported at $9.6 million in Q1 2026.
- Quarterly Operating Leases fell 54.54% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (down 54.54% YoY) and the FY2025 annual result came in at $11.1 million, down 35.23% from the prior year.
- Operating Leases slipped to $9.6 million in Q1 2026, from $11.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $33.5 million in Q2 2022 to a low of $9.6 million in Q1 2026.
- A 5-year average of $23.2 million and a median of $23.9 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases increased 1.34% — and 2026, when it slumped 54.54%.
- Tracing TVTX's Operating Leases over 5 years: stood at $27.5 million in 2022, then declined by 17.8% to $22.6 million in 2023, then fell by 23.97% to $17.2 million in 2024, then slumped by 35.23% to $11.1 million in 2025, then slipped by 14.08% to $9.6 million in 2026.
- The last three Operating Leases figures came in at $9.6 million (Q1 2026), $11.1 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.12 Mn |
| Mar 31, 2026 | 9.57 Mn |
| Dec 31, 2025 | 11.13 Mn |
| Sep 30, 2025 | 18.38 Mn |
| Jun 30, 2025 | 19.72 Mn |
| Mar 31, 2025 | 21.04 Mn |
| Dec 31, 2024 | 17.19 Mn |
| Sep 30, 2024 | 23.88 Mn |
| Jun 30, 2024 | 19.94 Mn |
| Mar 31, 2024 | 26.32 Mn |
| Dec 31, 2023 | 22.61 Mn |
| Sep 30, 2023 | 28.65 Mn |
| Jun 30, 2023 | 29.77 Mn |
| Mar 31, 2023 | 26.33 Mn |
| Dec 31, 2022 | 27.51 Mn |
| Sep 30, 2022 | 28.27 Mn |
| Jun 30, 2022 | 33.48 Mn |
| Mar 31, 2022 | 30.44 Mn |
| Dec 31, 2021 | 31.50 Mn |
| Dec 31, 2020 | 34.50 Mn |